Compliance to adjuvant endocrine therapy and survival in breast cancer patients.
-
Published:2023
Issue:
Volume:35
Page:100704
-
ISSN:2468-2942
-
Container-title:Cancer Treatment and Research Communications
-
language:en
-
Short-container-title:Cancer Treatment and Research Communications
Author:
Chamalidou ChaidoORCID,
Nasic Salmir,
Linderholm Barbro
Subject
Cancer Research,Oncology
Reference42 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018
2. Event-free survival with pembrolizumab in early triple-negative breast cancer;Schmid;N. Engl. J. Med.,2022
3. Trastuzumab emtansine for residual invasive HER2-positive breast cancer;Von Minckwitz;N. Engl. J. Med.,2019
4. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial;Johnston;Lancet Oncol.,2023
5. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer;Tutt;N. Engl. J. Med.,2021